City Holding Co. Has $52,000 Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

City Holding Co. lessened its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 46.3% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 753 shares of the biopharmaceutical company’s stock after selling 650 shares during the period. City Holding Co.’s holdings in Gilead Sciences were worth $52,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of GILD. Manning & Napier Advisors LLC bought a new position in shares of Gilead Sciences during the second quarter valued at $25,328,000. Juncture Wealth Strategies LLC raised its position in Gilead Sciences by 61.7% during the 2nd quarter. Juncture Wealth Strategies LLC now owns 7,092 shares of the biopharmaceutical company’s stock worth $487,000 after purchasing an additional 2,705 shares during the last quarter. Symmetry Partners LLC raised its position in Gilead Sciences by 18.5% during the 2nd quarter. Symmetry Partners LLC now owns 13,041 shares of the biopharmaceutical company’s stock worth $895,000 after purchasing an additional 2,037 shares during the last quarter. MADDEN SECURITIES Corp lifted its holdings in Gilead Sciences by 10.8% during the 2nd quarter. MADDEN SECURITIES Corp now owns 22,240 shares of the biopharmaceutical company’s stock worth $1,526,000 after buying an additional 2,175 shares during the period. Finally, Advocate Group LLC grew its position in shares of Gilead Sciences by 4.8% in the 2nd quarter. Advocate Group LLC now owns 77,650 shares of the biopharmaceutical company’s stock valued at $5,328,000 after buying an additional 3,580 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Stock Down 2.6 %

GILD stock traded down $1.93 during midday trading on Friday, reaching $73.66. 9,545,056 shares of the company’s stock traded hands, compared to its average volume of 7,396,841. The company has a quick ratio of 0.94, a current ratio of 1.08 and a debt-to-equity ratio of 1.31. The firm’s fifty day moving average price is $69.81 and its 200-day moving average price is $70.51. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $87.86. The company has a market cap of $91.77 billion, a price-to-earnings ratio of 204.61, a P/E/G ratio of 3.37 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.61 by $0.40. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The firm had revenue of $6.95 billion during the quarter, compared to analysts’ expectations of $6.64 billion. As a group, sell-side analysts forecast that Gilead Sciences, Inc. will post 3.73 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 27th. Stockholders of record on Friday, September 13th will be paid a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 4.18%. The ex-dividend date is Friday, September 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 855.56%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research report on Friday, April 26th. Maxim Group dropped their price target on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research report on Wednesday, May 1st. Morgan Stanley reduced their price objective on shares of Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating on the stock in a research note on Friday, April 26th. Barclays lowered their target price on shares of Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating for the company in a research note on Monday, April 29th. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $70.00 target price on shares of Gilead Sciences in a report on Friday. Twelve investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Gilead Sciences has a consensus rating of “Hold” and an average price target of $81.88.

Insider Activity

In related news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction on Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the sale, the insider now directly owns 96,380 shares of the company’s stock, valued at approximately $6,614,559.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.